ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Santen Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 6.50%
- The company has been able to generate a Return on Equity (avg) of 6.50% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 20.92
3
Poor long term growth as Operating profit has grown by an annual rate 1.43% of over the last 5 years
4
Positive results in Mar 26
- ROCE(HY) Highest at 12.81%
- RAW MATERIAL COST(Y) Fallen by -8.67% (YoY)
- NET SALES(Q) Highest at JPY 80,861 MM
5
With ROE of 10.76%, it has a fair valuation with a 1.92 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 18.26%, its profits have risen by 11% ; the PEG ratio of the company is 1.4
- At the current price, the company has a high dividend yield of 0
6
Majority shareholders : FIIs
7
Underperformed the market in the last 1 year
- The stock has generated a return of 18.26% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 81.96%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Santen Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.63%
EBIT Growth (5y)
1.43%
EBIT to Interest (avg)
20.92
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.92
Tax Ratio
24.14%
Dividend Payout Ratio
34.62%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
16.84%
ROE (avg)
6.50%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
1.92
EV to EBIT
12.58
EV to EBITDA
8.73
EV to Capital Employed
2.01
EV to Sales
1.80
PEG Ratio
1.42
Dividend Yield
NA
ROCE (Latest)
16.00%
ROE (Latest)
10.76%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
ROCE(HY)
Highest at 12.81%
RAW MATERIAL COST(Y)
Fallen by -8.67% (YoY
NET SALES(Q)
Highest at JPY 80,861 MM
OPERATING PROFIT(Q)
Highest at JPY 21,627 MM
OPERATING PROFIT MARGIN(Q)
Highest at 26.75 %
PRE-TAX PROFIT(Q)
Highest at JPY 19,366 MM
NET PROFIT(Q)
Highest at JPY 15,545 MM
EPS(Q)
Highest at JPY 47.75
-7What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at JPY 43,500 MM
INTEREST(Q)
At JPY 512 MM has Grown at 61.01%
DIVIDEND PAYOUT RATIO(Y)
Lowest at 39.3%
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.25 times
Here's what is working for Santen Pharmaceutical Co., Ltd.
Net Sales
Highest at JPY 80,861 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 21,627 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 26.75 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 19,366 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 15,545 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Net Profit
At JPY 15,545 MM has Grown at 77.01%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 47.75
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Raw Material Cost
Fallen by -8.67% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Santen Pharmaceutical Co., Ltd.
Operating Cash Flow
Lowest at JPY 43,500 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (JPY MM)
Interest
At JPY 512 MM has Grown at 61.01%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Inventory Turnover Ratio
Lowest at 2.25 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Dividend Payout Ratio
Lowest at 39.3%
in the last five yearsMOJO Watch
Company is distributing lower proportion of profits generated as dividend
DPR (%)
Non Operating Income
Highest at JPY 0.14 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
